Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Haioun, Corinne" or (type any "bookEditor issueEditor" and editor="Haioun, Corinne")

Add to list
- Journal Article
- A1
- open access
Prolonged remissions after nivolumab plus gemcitabine/oxaliplatin in relapsed/refractory T-cell lymphoma

Roch Houot, Viola Poeschel, Bettina Altmann, Stephanie Angel, Lorenz Thurner, Thomas Illmer, Marc Andre, Martin Dreyling, Herve Maisonneuve, Herve Tilly, et al.

(2022) HEMASPHERE. 6(2).
Add to list
Glofitamab step-up dosing (SUD) : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (Pts)

Carmelo Carlo-Stella, Cyrus Khan, Martin Hutchings, Fritz Offner (UGent) , Franck Morschhauser, Emmanuel Bachy, Michael Crump, Anna Sureda, Gloria Iacoboni, Corinne Haioun, et al.

(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S394-S394
Add to list
- Conference Paper
- C3
Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the niveau trial

Roch Houot, Viola Poeschel, Bettina Altmann, Thomas Illmer, Marc Andre, Martin Dreyling, Herve Maisonneuve, Herve Tilly, Stephanie Mayer, Rene-Olivier Casasnovas, et al.

(2020) BLOOD. 136(Suppl. 1). p.33-34
Add to list
- Journal Article
- A1
- open access
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma : an analysis of two LYSA studies

Aurélie Cabannes-Hamy, Frederic Peyrade, Fabrice Jardin, Jean-François Emile, Vincent Delwail, Nicolas Mounier, Corinne Haioun, Aurore Perrot, Olivier Fitoussi, Diane Lara, et al.

(2018) CANCER MEDICINE. 7(3). p.539-548
Add to list
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma : a retrospective training and validation analysis in three international cohorts

Sarah Huet, Bruno Tesson, Jean-Philippe Jais, Andrew L Feldman, Laura Magnano, Emilie Thomas, Alexandra Traverse-Glehen, Benoit Albaud, Marjorie Carrere, Luc Xerri, et al.

(2018) LANCET ONCOLOGY. 19(4). p.549-561
Add to list
- Conference Paper
- C3
Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years

Gilles Andre Salles, John Francis Seymour, Pierre Feugier, Fritz Offner (UGent) , Armando Lopez-Guillermo, David Belada, Luc Xerri, Reda Bouabdallah, John Catalano, Pauline Brice, et al.

(2017) BLOOD. 130(suppl. 1).
Add to list
Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Vincent Ribrag, Hervé Tilly, Olivier Casasnovas, André Bosly, Reda Bouabdallah, Richard Delarue, François Boue, Dominique Bron, Pierre Feugier, Corinne Haioun, et al.

(2013) EUROPEAN JOURNAL OF CANCER. 49(4). p.904-910
Add to list
- Conference Paper
- C3
Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy

Gilles André Salles, John Francis Seymour, Pierre Feugier, Fritz Offner (UGent) , Armando Lopez-Guillermo, David Belada, Luc Xerri, Reda Bouabdallah, John Catalano, Brice Pauline, et al.

(2013) BLOOD. 122(21).
Add to list
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John Francis Seymour, Fritz Offner (UGent) , Armando López-Guillermo, David Belada, Luc Xerri, Pierre Feugier, Réda Bouabdallah, John Vincent Catalano, Pauline Brice, et al.

(2011) LANCET. 377(9759). p.42-51

Academic Bibliography

Prolonged remissions after nivolumab plus gemcitabine/oxaliplatin in relapsed/refractory T-cell lymphoma

Glofitamab step-up dosing (SUD) : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (Pts)

Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the niveau trial

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma : an analysis of two LYSA studies

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma : a retrospective training and validation analysis in three international cohorts

Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Contents

Support

Contact